Physician profile
Abraham E Soroudi
NPI 1326092529
$7,151.85
in general payments reported to CMS, 2019-2025
25 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $502 · 2021: $1,110 · 2022: $999 · 2023: $814 · 2024: $893 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323 · Entertainment: $13.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.82 |
| Entertainment | $13.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,271.53 | 2019-2025 | Clareon, Wavelight Ex500 Excimer Laser, Centurion |
| Abbvie INC. | $1,555.75 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Allergan, INC. | $582.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $523.98 | 2019-2023 | |
| Glaukos Corporation | $444.10 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $258.83 | 2019-2025 | Tecnis Iol |
| Dompe US, INC. | $200.57 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $183.36 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $175.65 | 2019-2021 | |
| Oyster Point Pharma, INC. | $157.02 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rxsight INC | $87.54 | 2022-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Harrow Eye, LLC | $86.79 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $83.38 | 2019-2021 | |
| Sight Sciences, INC. | $76.12 | 2020-2023 | Tearcare System |
| Baxter Healthcare | $62.29 | 2024 | Tisseel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $61.18 | 2019 | |
| Bausch & Lomb Americas INC. | $59.71 | 2022 | |
| Shire North American Group INC | $58.96 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $55.89 | 2024 | Xdemvy |
| Thea Pharma INC. | $41.12 | 2024 | Iyuzeh |
| Biotissue Holdings INC. | $38.91 | 2022 | |
| Amgen INC. | $29.62 | 2024 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $23.51 | 2021 | |
| Omeros Corporation | $19.40 | 2021 | |
| Optos, INC. | $13.77 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Soroudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.